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Pleural mesothelioma is an aggressive malignancy with limited effective therapies. In order to 
identify therapeutic targets, we integrated SNP genotyping, sequencing and transcriptomics from 
tumours and low‑passage patient‑derived cells. Previously unrecognised deletions of SUFU locus 
(10q24.32), observed in 21% of 118 tumours, resulted in disordered expression of transcripts from 
Hedgehog pathways and the T‑cell synapse including VISTA. Co‑deletion of Interferon Type I genes and 
CDKN2A was present in half of tumours and was a predictor of poor survival. We also found previously 
unrecognised deletions in RB1 in 26% of cases and show sub‑micromolar responses to downstream 
PLK1, CHEK1 and Aurora Kinase inhibitors in primary mesothelioma cells. Defects in Hippo pathways 
that included RASSF7 amplification and NF2 or LATS1/2 mutations were present in 50% of tumours 
and were accompanied by micromolar responses to the YAP1 inhibitor Verteporfin. Our results suggest 
new therapeutic avenues in mesothelioma and indicate targets and biomarkers for immunotherapy.
Pleural mesothelioma is an aggressive malignancy associated with asbestos exposure. Global mesothelioma 
deaths are estimated to be 38,400 each  year1. Mesothelioma is usually refractory to known treatments. Although 
20% of tumours may transiently regress after checkpoint  immunotherapy2,3, PD-L1 is expressed at a low level in 
the majority of mesothelioma  cases3 and predictors of response are unknown. The molecular landscape is not 
complex but to date known recurrent lesions have not yet defined effective therapeutic  targets4,5.
Intense fibrosis typically accompanies mesothelioma and may cause intractable pain and dyspnoea. For 
example, in the UK MesobanK tumour  repository6 65% of mesothelioma have < 25% of tumour cells visible on 
surgical biopsy and only 8% of mesothelioma comprise > 75% malignant cells. This suggests the tumour-matrix 
interaction to be a feature of the disease.
Inflammation and fibrosis in the pleura are normally adaptive mechanisms that seal off foci of injury or 
infection. Incomplete macrophage phagocytosis of inhaled high-aspect ratio asbestos fibres induces sustained 
inflammation and cytokine  release7,8, increased mesothelial proliferation, oxidative DNA  damage9 and double 
strand DNA  breakages10 that can cause malignant transformation.
Previous genomic analyses of mesothelioma have shown a mutational landscape dominated by loss of func-
tion mutations in BAP1 and NF24,5. Larger structural variations in mesothelioma are  common11, and recurrent 
deletions are recognised for CDKN2A (located at chromosome 9p21.3), NF2 (22q12) and BAP1 (3p21.3).
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Given the proclivity for asbestos to induce DNA damage, we extended genomic findings in 121 mesothelioma 
tumours by fine mapping of copy-number alterations (CNAs) with high-density SNP arrays. We explored the 
mutational spectrum with whole exome sequencing (WES) in 50 subjects (21 of which had paired blood samples 
for germline DNA), before extending mutation detection to all tumours with a 57-gene targeted capture next-
generation sequencing (TC-NGS) panel (Supplementary File 1_Fig. 1a, b and Supplementary File 1_Table 1). 
In addition, we whole-genome sequenced (WGS) 19 low-passage primary mesothelioma derived cell cultures 
(PMCC)12.
Results
Demographic and clinical characteristics. One hundred and five of the 121 patients (87%) were male 
(Supplementary File 1_Table 2). Ninety tumours exhibited the epithelioid subtype of mesothelioma, 25 were 
biphasic and 6 were sarcomatoid (Supplementary File 1_Fig. 1c). Patients with sarcomatoid disease were older 
than the other two groups (P = 0.05). Asbestos exposure had been documented clinically in 69% of cases. The 
median overall survival (OS) for all subjects was 9.9 months with sarcomatoid patients showing a worse outcome 
than others, (P = 0.065) (survival time from diagnosis to death or last follow-up was available for 110 patients; 
Supplementary File 1_Table 2 and Supplementary File 1_Fig. 1d; Supplementary File 2_Table 1), as  described13.
Given the wide variability between the proportions of mesothelioma malignant cells and matrix fibrosis, we 
estimated the tumour content of all samples with ASCAT analysis of the > 950 K SNPs in the Illumina Infinium 
OmniExpressExome-8 v1.3 and v1.4 panels. We found the median tumour content was 0.44 (range 0.2–1.0; 1st 
quartile 0.32; 3rd quartile 0.9; median absolute deviation 0.22).
Copy number alterations (CNAs) analysis shows recurrent CDKN2A, RB1 and SUFU deletion 
and RASSF7 amplification. We analysed the SNPs for CNAs using the GISTIC  program14. The program 
estimates genomic boundaries for recurrent CNA events and assigns statistical significance after false discovery 
rate (FDR) corrections.
Deletion of CDKN2A was the most frequent event observed in our samples, detected in 71/118 tumours 
(60%), with 58 deletions (82%) predicted to be homozygous (Figs. 1a, 2). As previously  reported15, CDKN2A dele-
tion was associated with worse OS compared with CDKN2A wild type patients (8.8 vs 13.0 months, Kaplan–Meier 
P = 0.02) (Fig. 1c), and with increased copy number burden (Supplementary File 2_Table 5A).
Deletion of the CDKN2A region is extensive in many malignancies and a full locus map (Fig. 1b) revealed 
large deletions to also be present in mesothelioma. The map revealed a frequent deletion of the closely neigh-
bouring Type I Interferon (IFN) genes, as we have first  reported16 and has later been  confirmed17 (Fig. 1b and 
Supplementary File 2_Table 6): 38/118 patients (32%) had predicted homozygous IFN Type I deletion and 
24/118 (20%) had heterozygous deletion. The median survival of patients with co-deletion of CDKN2A and IFN 
Type I genes was not statistically different to CDKN2A deletions alone (8.3 months compared to 10.7, P = 0.6; 
Supplementary File 2_Table 6).
We observed frequent deletions at multiple other loci (Fig. 1d-f, Supplementary File 1_Table 3 and Supple-
mentary File 2_Table 5B for the extensive list of copy-number coordinates for each sample). The most common 
novel deletion was the RB1 locus on 13q14.2 in 31/118 patients (26%). The RB1 tumour suppressor is activated 
downstream of CDK4 and  CDK618 and its deletion predicts a mechanism for resistance to CDK4/6 inhibitors.
Deletion of a locus on 10q24.32 containing SUFU (Suppressor of Fused), ARL3 (ADP Ribosylation Factor Like 
GTPase 3) and TRIM8 (Tripartite Motif Containing 8) was observed in 25/118 tumours (21%). SUFU inhibits 
activation of GLI transcription factors in the Hedgehog pathway, which is known to be disordered during meso-
thelioma  carcinogenesis19,20. TRIM8 acts as a tumour suppressor inducing cell cycle arrest in a TP53 dependant 
manner, and as an oncogene activating NF-kβ and TNF-α21. It is involved both in immunity and  cancer22.
Previously unrecognised regions of amplification (Figs. 1a, 2, Supplementary File 1_Table 3 and Supple-
mentary File 2_Table 5B for the extensive list of copy-number coordinates for each sample) included a locus on 
11p15.5, amplified in 39/118 tumours (33%) that contained RASSF7 and miR-210 (Fig. 1g). When up-regulated 
RASSF7 controls cell growth and apoptosis in different  tumours23, and functions as an oncogene in NSCLC, 
interacting with MST1 to dysregulate Hippo  signalling24.
Other substantial amplifications included 19q13.43 in 24/118 tumours (20%), containing NLRP5, ZNF444 
and ZNF787; 5q35.2 in 27/118 tumours (23%), containing GPRIN1 immediately adjacent to CDHR2 which may 
moderate contact inhibition of epithelial cell  growth25; and 5q35.3 in 26/118 tumours (22%) containing LTC4S 
and SQSTM1. The latter encodes p62, a mediator of autophagy influencing tumorigenesis, malignant growth 
and resistance to  therapy26.
We sought replication of the novel CNAs in 98 tumours from the landmark study of Bueno et al.5 which car-
ried out WES and concurrent RNA-sequencing. We confirmed amplification of RASSF7 and deletion of RB1 and 
SUFU, each of which correlated with its transcript abundance (Supplementary File 1_Fig. 4 and Supplementary 
File 2_Table 7).
Deletion of SUFU locus, component of Hedgehog signalling pathway, is associated with 
downregulation of immune related genes. Deletion of the SUFU locus in 25/118 tumours (21%) was 
associated with marked upregulation of the Patched 2 tumour suppressor (PTCH2) (Table 1). Ptch2 overexpres-
sion has been observed in Sufu knockout mice and is indicative of aberrant Hedgehog  signalling20. Hedgehog 
pathways are activated in mesothelioma patients, in the absence of obvious  mutations19. Also, upregulated were 
NHS, HOXA7 and TRPS1, each of which regulate tissue differentiation (Table 1).
We found a SMO (Smoothed) inhibitor (Vismodegib, GDC-0499) to be inhibitory in only one PMCC 
(Table 2). Vismodegib has previously been shown to be effective in modulating mesothelioma tumour and 
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Figure 1.  Mapping of copy number alterations in subjects with pleural mesothelioma. (a) Statistically significant regions of 
amplification and deletion from GISTIC analysis of 118 subjects. Peak regions which pass both the G-Score ( Gistic score in ver.2.0 is 
defined as the negative logarithm of the probability of observing a candidate copy-number segment with given amplitude and frequency, 
provided the background copy-number alteration rate) and q-bound (< 0.05) threshold cut-offs are shown for deletions (blue) and 
amplifications (red) (see also Supplementary File 1_Table 3 and Supplementary File 2_Table 5B for the extensive list of copy-number 
segment coordinates for each sample); (b) Detailed map of the CDKN2A locus using the UCSC Genome Browser (hg19), showing 
histogram representation of overlap among deletion segments from the 118 subjects. IFN Type I genes are commonly within the deleted 
segments; (c) Kaplan–Meier survival analysis of patients with and without CDKN2A locus deletions; (d-f) Similar Genome Browser 
based maps of the BAP1, RB1 and SUFU deleted segments; (g) Map for amplification segments from the RASSF7 locus.
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stromal interactions in a rat model of  mesothelioma27, suggesting beneficial effects of Hedgehog inhibition would 
be worthy of investigation in mixed cellular cultures of human mesothelioma.
SUFU deletion unexpectedly correlated with downregulation of prominent T-cell genes (Table 1), includ-
ing ODF3B; the killer-cell receptor KLRD1 (CD94); and HSH2D, a target of T-cell activation. Downregulated 
monocyte/macrophage and dendritic cell markers included IL4R, SCIMP, SIGLEC1 (CD169), CLEC10A, and 
CR1 (Complement C3b/C4b receptor 1).
We confirmed these results in the large independent dataset from Bueno et al.5, confirming that abundances 
of Hedgehog pathway transcripts SUFU, PTCH1 and PTCH2 correlated with KLRD1 and CR1 (Supplementary 
File 1_Table 5).
Hippo pathway is deregulated in 50% of mesothelioma patients due to RASSF7 amplifica‑
tion and NF2, LATS1/2 mutations. Hippo monitors external factors that shape tissue  structure28. NF2 
recruits core Hippo signalling pathway members (LATS1/2) to inhibit activation of the transcriptional cofactors 
YAP1 and  TAZ29. RASSF7 also regulates Hippo pathways, and its overexpression promotes phosphorylation 
and nuclear translocation of  YAP124. We found RASSF7 amplification in 39 mesotheliomas, NF2 mutations 
in 24, LATS2 mutations in 6 and LATS1 in 2, so that non-overlapping lesions in Hippo pathways were present 
in 52/121 mesotheliomas (43%) and a further 9 mesothelioma had more than one lesion (total 50%) (Fig. 2). 
WNT5B transcription, which we found increased in sarcomatoid tumours, may also induce YAP/TAZ activation 
through non-canonical  pathways30.
We did not find significant differences in transcript abundances when comparing RNA-sequencing derived 
transcriptomes for RASSF7 amplifications to other tumours; or for lesions in Hippo signalling genes (NF2, LATS1, 
LATS2) singly or combined; or for mesotheliomas with or without SETD mutations. We did not detect RASSF7 
amplification in any of 19 primary cell lines examined by WGS and SNP array (Supplementary File 1_Fig. 5), 
which may reflect selection in culture for mesothelioma genotypes that grow independently of a fibroblast matrix.
Figure 2.  Common genetic alterations in Pleural Mesothelioma. The most common deletions (top panel), 
amplifications (middle panel) and mutations (bottom panel) are shown in 118 subjects. CNA analyses are 
derived from SNP arrays and mutated genes from the targeted capture sequencing panel.
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Table 1.  Genes differentially regulated with SUFU locus deletions.
Log2 Fold Change Av. Exp P P Adj Chr Name Description
3.66 1.95 2.23E−05 3.09E−02 1 PTCH2 Patched 2 tumour suppressor, indicative of aberrant Hedge-hog signalling
2.82 3.91 4.61E−05 3.64E−02 13 GJB2 Gap junction protein beta 2
2.78 3.53 1.15E−04 4.36E−02 12 NXPH4 Neurexophilin 4
2.35 1.35 1.18E−04 4.37E−02 X NHS Regulates actin remodelling and cell morphology
2.32 1.77 1.12E−04 4.32E−02 7 HOXA7 Transcription factor regulating morphogenesis and dif-ferentiation
1.26 3.26 1.20E−04 4.38E−02 8 TRPS1 Transcriptional repressor GATA binding 1
1.09 2.94 4.48E−05 3.64E−02 1 C1orf112 Chromosome 1 open reading frame 112
− 1.06 4.79 7.90E−06 2.85E−02 10 ZFYVE27 Zinc finger protein
− 1.11 5.89 1.18E−04 4.37E−02 16 IL4R Interleukin 4 receptor
− 1.11 5.30 4.78E−05 3.64E−02 10 ERLIN1 Binds cholesterol and regulates SREBP signalling pathway
− 1.15 4.37 1.51E−05 2.85E−02 10 FBXL15 F-box and leucine rich repeat protein 15
− 1.18 7.24 7.23E−05 3.95E−02 10 WBP1L WW domain binding protein 1-like
− 1.33 4.54 3.28E−05 3.43E−02 10 SUFU Negative regulator of hedgehog signalling
− 1.49 6.14 1.72E−05 2.85E−02 6 CCND3 Regulatory subunit of CDK4 or CDK6, involved in phospho-rylation Rb1
− 1.51 6.19 1.10E−05 2.85E−02 3 DTX3L Deltex E3 ubiquitin ligase
− 1.52 5.09 6.97E−05 3.95E−02 22 ODF3B Differentially regulated in pathogenic CD4(+) T cells in MS
− 1.55 7.58 1.05E−04 4.20E−02 10 MYOF May be involved in membrane regeneration and repair
− 1.58 4.43 6.91E−06 2.85E−02 18 EPB41L3 Erythrocyte membrane protein like
− 1.63 2.83 9.32E−05 4.11E−02 17 SCIMP TLR adaptor promotes cytokine production from mac-rophages; involved in MHC class II signalling
− 2.13 4.41 9.12E−06 2.85E-02 10 AVPI1 Arginine vasopressin induced 1
− 2.19 5.23 2.04E−05 3.09E−02 20 SIGLEC1 CD169: CD169 macrophages dominate antitumor immunity by presenting dead cell antigens
− 2.24 5.86 7.82E−05 3.95E−02 10 IFIT3 IFN-independent upregulation of IFN-stimulated Genes during CMV infection
− 2.27 5.68 3.33E−05 3.43E−02 12 OAS2 Involved in the innate immune response to viral infection
− 2.67 3.10 1.09E−04 4.26E−02 17 CLEC10A Specific Marker for human CD1c + dendritic cells: enhances TLR7/8-induced cytokine secretion
− 2.73 1.58 1.39E−04 4.86E−02 12 KLRD1 CD4: Killer cell receptor, may be involved in the regulation of NK cell function
− 2.97 1.89 1.76E−05 2.85E−02 1 CR1 Complement C3b/C4b receptor 1: found on dendritic and other cells
− 3.08 2.61 4.28E−05 3.64E−02 19 HSH2D Target of T-cell activation signals: TCR antigen recognition, and co-stimulation by CD28
− 3.56 3.19 1.36E−04 4.82E−02 11 HRASLS5 HRAS like suppressor family member 5
Table 2.  IC50 values for responses normalized to the control (DMSO), calculated by fitting a dose–response 
curve model in Graph Pad Prism and tabulated as concentration of drugs in µM. In cases where responses 
were above the highest drug concentration used in the experiment,  IC50 estimates are marked as > 50 µM. 
Values in bold depict sensitive primary cells and cell lines, where  IC50 to compounds < 10 µM and  R2 (goodness 
of fit of curve) > 0.7).
DNA repair Hedgehog Hippo Cell cycle RB1
Niraparib Olaparib Vismodegib Verteporfin Palbociclib Alisertib Volasertib AZD7762









Meso-27T 7.96 10.52 31.53 1.08  > 50 3.20 6.57 0.45
Meso-33T 47.02  > 50 6.03 0.87 20.29 3.84 0.10 0.45
Meso-70T  > 50 2.88  > 50 1.2  > 50 0.15 0.04 2.02
NCI-H2052 29 27.3 13.7 10.9  > 50 0.81 0.64 2.42
A549  > 50 13.47 20.72 16.5 12.33 11.7 0.71 1.84
Met-5A  > 50 11.13 8.53 3.36 29.2  > 50 0.44 0.11
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Investigation of somatic mutations confirms the major driver genes in mesothelioma. WES 
in 50 tumours (mean coverage 136X; 21 with paired peripheral blood lymphocyte DNA (PBL)) revealed no 
major loci beyond those previously  described4,5 (Supplementary File 2_Table 2). We successfully completed TC-
NGS in 119 patients (Supplementary File 2_Table 3 and Supplementary File 1_Fig. 1b), 77 of which had paired 
PBL, achieving a mean coverage of 792X for tumours and 802X for PBL. BAP1 was mutated in 39 subjects (33%); 
NF2 in 24 subjects (20%); TP53 in 9 subjects (8%) and SETD2 in 7 subjects (6%) (Fig. 2 and Supplementary 
File 1_Fig. 2). Mutations were scattered across coding regions of these genes (Supplementary File 1_Fig. 3b-d), 
consistent with their putative role as tumour suppressors.
We found two NRAS mutations at known oncogenic RAS hotspots (G12V and Q61H). Both mutations were 
found in sarcomatoid subtype tumours that did not have alterations in CDKN2A, BAP1 or NF2. In the TCGA-
Meso cohort, only one patient with biphasic histology had a G12C KRAS hotspot mutation with a concurrent 
TP53 mutation but without alterations in other mesothelioma drivers, similar with our cohort. In the Bueno 
et al.5 cohort also only one patient with sarcomatoid subtype had a Q61K NRAS mutation but this was detected 
simultaneously with a BAP1 frameshift mutation. We also identified three other RAS pathway related genes by 
WES: a NF1 stop mutation (c.6439C > T, p.Q2147*), a splice site RASA1 mutation (c.829-1_858.del) and a HRAS 
in-frame deletion (c.187_189del, p.E63del).
TP53 mutations carried a worse prognosis compared with TP53 wild-type counterparts (mean OS 5.7 vs. 
13.6 months, P = 0.0005), as previously  described5. We did not detect significant associations of other mutations 
with survival.
Combined analysis of CNA, WES and TC-NGS (Fig. 2) showed CDKN2A deletion to be present in 60% of 
tumours; BAP1 mutated or deleted in 54%; RASSF7 amplification in 33%; RB1 deleted or mutated in 26%; NF2 
mutated in 20%; TP53 mutated in 8%; SETD2 in 6%; DDX3X in 5% and LATS2 in 5%.
We detected a missense germline mutation localized in the UCH domain of BAP1 from one patient with 
epithelioid subtype (Supplementary File 1_Fig. 3b). In other subjects, single deleterious germline mutations 
were found in MSH5 and MSH6 (representing the mismatch-repair (MMR) pathway), RB1, SETD6 and BRCA2.
BAP1 is the most common mutated gene in mesothelioma and is associated with up‑regu‑
lation of RET. We explored the effects of genetic alteration by comparing RNA-sequencing samples with 
and without specific genetic alterations. When compared to other tumours, BAP1 mutations or deletions were 
associated (Padjusted < 0.05) with up-regulation of the RET proto-oncogene31 and NNAT.  NNAT overexpression is 
associated with poor outcome in multiple  cancers32 (Supplementary File 1_Table 6). We replicated the negative 
association of BAP1 with RET to be present also in the Bueno et al.5 (r = −0 .32, P = 2.2E−06) and TCGA-Meso4 
(r = − 0.45, P = 1.3E−06) datasets.
Mutational signatures 1 and 3 are prevalent in mesothelioma. A median of 31 non-synonymous 
somatic mutations per tumour exome were present in the 21 WES paired samples, consistent with the low rate 
observed by Bueno et al.5. We observed a similar low tumour mutational burden in the 77 paired samples that 
underwent targeted capture sequencing (Supplementary File 1_Fig. 3i).
One patient (NCMR035) had a hypermutated tumour (167 somatic mutations from WES) (Supplementary 
File 1_Fig. 6), accompanied by a frame-shift deletion in MSH6 (p.Phe1104LeufsX11) and a frame-shift insertion 
in PALB2 (p.Met1049AspfsX4). PALB2 encodes a protein that recruits BRCA2 and RAD51 at the site of double-
strand  breaks33 and plays a critical role in homologous recombination repair.
The mutation spectrum was characterized by C > T transitions, in both WES and TC-NGS panel data (Supple-
mentary File 1_Fig. 3 and 3a respectively), consistent with earlier  reports4,5. Analysis of mutational  signatures34,35 
found COSMIC signatures 1 and 3 to be prevalent in the 21 paired WES samples (Supplementary File 1_Fig. 3e, 
f) and in WGS from 19  PMCC12 (Supplementary File 1_Fig. 3g, h).
Signature 3 is indicative of DNA damage and failed breakpoint  repair35. In other cancers, signature 3 muta-
tions often accompany biallelic inactivation of BRCA1 or BRCA2, where the inability to repair DNA predicts 
good responses to platinum therapy. Mesothelioma responds poorly to such therapies, and we hypothesise that 
signatures of DNA damage may follow the actions of asbestos in the progenitor neoplastic cell.
WNT5B is higher expressed in sarcomatoid tumours. We did not see any significant associations 
between common lesions and histological subtypes. RNA-sequencing however revealed differential transcrip-
tion between histologies (Supplementary File 1_Table 4). As reported  previously5, WNT5B had higher expres-
sion in sarcomatoid and mixed histology tumours compared to epithelioid tumours. Other genes significantly 
upregulated (Padjusted < 0.001) in non-epithelioid tumours included GPR176 which acts as a circadian  pacesetter36, 
and known adverse factors for other cancers such as IGF2BP1, CCBE1, HS3ST3A1, TRAM2 and SERTAD2.
High level of VISTA is frequent in epithelioid mesothelioma and its expression level correlates 
with Hedgehog and immune pathway components. We tested how the most frequent genomic 
alterations, BAP1 mutation and CDKN2A deletion, were translated at protein levels. We stained a subset of 28 
tumours (Fig. 3a) with antibodies against BAP1 and MTAP (as a potential surrogate marker for CDKN2A dele-
tion) along with PD-L1, VISTA, Ki-67 and an antibody for mitotic count (Fig. 3b-e).
BAP1 staining revealed general or focal loss in 17/28 (61%) of cases, which only partially associated with 
BAP1 mutation or deletion (P = 0.01) (Fig. 3f), as previously  suggested37. There was significant difference when 
comparing MTAP H-score between CDKN2A/MTAP deleted and wild-type samples (P = 0.001) (Fig. 3g). The 
mitotic count and Ki-67 (both indicators of proliferation) correlated with each other (P < 0.0001, r = 0.42). Ki67 
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Figure 3.  Histologic features of pleural mesothelioma. (a) Oncoplot of IHC staining and common genomic 
alterations; three colour coded panels are shown: the upper panel represents the histological subtype of the 
samples, the middle panel shows antibody staining for the proteins denoted on the left hand side of the panel 
(antibody staining were assessed as percentages, with the exception of BAP1; representation in the figure was 
done by grouping samples based on different percentage ranges that are shown in the legend on the right hand 
side of the panel) and the bottom panel shows any genomic alteration (mutation or copy number alteration) 
in the analysed samples; (b-e) Representative IHC images for PD-L1, MTAP and BAP1 (100 ×); (f) Analysis 
on BAP1 genomic and proteomic status by Fishers` exact test; (g) Analysis of MTAP H-score in CDKN2A/
MTAP deleted vs CDKN2A/MTAP wild-type by Fisher`s exact test, with a threshold for MTAP H-score set at 
50; (h) Spearman correlation between PD-L1 gene expression and IHC.
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correlated with copy number burden (P = 0.03, r = 0.42) and with MTAP score (P = 0.04, r = 0.39), consistent with 
disordered cellular division accompanying CDKN2A deletion.
Checkpoint inhibitors targeting PD-1 and its ligand PD-L1 cause marked tumour regression in some patients 
with  mesothelioma3. However, PD-L1 is expressed at a low level, if at all, in most mesothelioma cases and its 
status imperfectly predicts response to immune checkpoint  inhibitors3.
In our tumours, IHC staining for PD-L1 was also low, with only 4/28 cases (14%) exhibiting ≥ 10% expres-
sion, including one case > 70%. There was a good correlation between PD-L1 (SP263) staining and transcript 
abundance (P < 0.01, r = 0.7) (Fig. 3h). We did not see a consistent relationship between any Hedgehog-related 
transcripts and PD-L1 in transcriptomic data (Supplementary File 1_Table 5).
High-level staining of the alternative immune-checkpoint protein VISTA (V-domain Ig suppressor of T cell 
activation)38 has been observed in epithelioid mesothelioma, and implies a better  prognosis4,39. We confirmed a 
high level of VISTA by IHC in our samples (Fig. 3a), and in RNA-sequencing data replicable associations were 
seen between VISTA and SUFU, PTCH1, PTCH2, KLRD1 and CR1 (Supplementary File 1_Table 5).
Drug‑testing shows that primary cell models of mesothelioma are sensitive to cell cycle tar‑
geted drugs. We explored potential therapeutic pathways that had been suggested by our genomic findings 
by determining the half maximal inhibitory concentration  (IC50) of selected compounds with three  PMCC12 that 
had been whole-genome sequenced (Supplementary File 1_ Fig. 5). We assessed by Western blots if deletions or 
mutations of the main mesothelioma drivers were translated to protein levels (Supplementary File 1_Fig. 7a). 
For comparison, we included an immortalized mesothelioma cell line (H2052), a lung adenocarcinoma cell line 
(A549), and a transformed normal mesothelial cell line (Met-5A). We exposed cells to a range of drug concentra-
tions (0.0005 to 50 micromolar (µM)) using as controls DMSO treated cells (Supplementary File 1_Fig. 7b-g).
As we had observed mutation signatures associated with repair of DNA double-strand breaks (COSMIC 
mutational signature 3), we tested two PARP inhibitors (Niraparib and Olaparib) that are effective in homologous 
repair  deficiency40. Despite reports suggesting utility in  mesothelioma41, we did not see a consistent inhibition 
of primary cell growth (Table 2). Our results are supported by a recent report by Fennell et al.42 that tested Ruca-
parib, a third PARP inhibitor, in BAP1 or BRCA1 defective mesothelioma patients. Although the clinical trial 
achieved its endpoints, the author suggested that there is no correlation between BAP1 or BRCA1 expression 
and patients’ objective response to Rucaparib.
Another tested drug in our screen, Palbociclib, PD0332991, a CDK4/CDK6 inhibitor, that is supposed to tar-
get the most frequent deletion in mesothelioma, CDKN2A, showed only minor effects in our cell lines (Table 2).
RB1 deletion has recently been shown to confer a robust and selective vulnerability to drugs that target 
DNA damage checkpoint (CHEK1) and chromosome segregation proteins such as Polo-Like-Kinase 1 (PLK1)43. 
CHEK1 is over-expressed in  mesothelioma44, and RNAi screens have shown mesothelioma lines to be sensitive 
to CHEK1 and PLK1 knockdown. RB1 deficient tumours are hyper-dependent on Aurora kinase B (AURKB) 
for  survival45, and AURKB inhibitors are efficacious against RB1 deficient lung cancers at non-toxic  doses45. 
Consistent with these observations, we found micromolar (µM) to sub-µM responses when treating with an 
Aurora Kinase inhibitor (Alisertib, MLN8237); an inhibitor of PLK1/2/3 that induces G2/M arrest and apoptosis 
(Volasertib, BI6727)46; and a CHEK1/2 inhibitor that abrogates the G2/S checkpoint (AZD7762).
The involvement of Hippo pathways in our results supports previous suggestions that YAP1 axis inhibition 
may be used in mesothelioma  therapy29. We found µM  IC50 responses to the YAP inhibitor Verteporfin in all 
mesothelioma cell lines (Table2). Notably, immortalised Met-5A mesothelial cells that are not deficient in NF2 
also responded.
Discussion
In our study we have extended previous genomic analyses by testing copy number aberrations (CNAs) through 
SNP genotyping arrays together with WES and targeted capture sequencing. We found genetic lesions to be 
enriched in RB1/cell-cycle, Hippo and Hedgehog pathways, and identified two major immunological influences. 
We assessed vulnerabilities of mesothelioma tumours by testing drugs that target altered pathways or their 
members in whole genome sequenced primary mesothelioma cells.
The most frequent genomic alteration in our subjects was deletion of the CDKN2A locus on 9p21.3, found in 
60% of the analysed samples. This deletion predicts a worse OS than tumours without the  deletion47. We observed 
that tumours with this deletion had a higher copy number burden compared with CDKN2A wild type patients, 
consistent with cell cycle dysregulation.
Hippo pathway activation was observed in more than 50% of mesothelioma tumours while Hedgehog pathway 
activation, as SUFU deletion, was seen in 21% of the tumours.
Cdkn2a deletion and Hedgehog and Hippo pathway activation have been observed in murine models of 
asbestos exposure well before tumour  development7,8,19. Our results and the remarkable consistency of genetic 
lesions in mesothelioma in  humans4,5 and in  mice7,8 suggest a hypothesis that recurrent mesothelioma break-
points and mutations occur in regions of chromatin that have been accessed during the inflammatory response to 
asbestos. Activation of Hedgehog might also contribute to the stroma-rich microenvironment that characterises 
mesothelioma tumours.
Our finding of RB1 deletions in 34% of tumours with CDKN2A deletion makes responses to CDK4/CDK6 
antagonists less likely and underpins our finding that the CDK4/CDK6 inhibitor Palbociclib had marginal effects 
on primary cell survival. However, we note a previous publication has reported mesothelioma cell lines to be 
sensitive to this  compound48 and further investigations are indicated.
We therefore tested compounds downstream of RB1 and showed that RB1 defective primary cells responded 
well (irrespective of CDKN2A deletion) to an Aurora Kinase inhibitor (Alisertib, MLN8237); an inhibitor of 
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PLK1/2/3 that induces G2/M arrest and apoptosis (Volasertib, BI6727) and a CHEK1/2 inhibitor (AZD7762). 
These findings encourage the clinical investigation of these or related compounds, and a Phase II Trial of Alisertib 
in salvage malignant mesothelioma is currently under way (NCT02293005).
We identified a recurrent novel amplification of RASSF7 in 31% of tumours. Taken with other Hippo path-
way members (NF2, LATS1 and LATS2), 50% of tumours had at least one lesion of this pathway. Our testing of 
primary cells revealed micromolar responsiveness of mesothelioma to the YAP inhibitor Verteporfin, although 
it did not seem to depend on the presence of NF2 or other Hippo mutations. These results are consistent with 
recent studies that have shown Verteporfin to be effective in vitro against mesothelioma  cells49,50.
BAP1 is the archetypal mesothelioma  gene51 and was mutated in 31% of tumours and deleted in 33%. We 
gained some insight into its function by comparing transcriptome abundances between BAP1 mutation/dele-
tion and BAP1 wild type tumours, where we found replicated up-regulation of the RET proto-oncogene. These 
results suggest tumour suppressor activities of BAP1 beyond  deubiquitination52. It may be of interest that RET 
inhibitors are effective in RET-driven NCSLC and thyroid  cancers53.
An important finding of our study was deletion of the SUFU locus on chromosome 10q24.32 in 21% of 
tumours. However, we did not find SUFU deletions in primary cells and Vismodegib, a Hedgehog inhibitor, was 
efficient in only one primary cell line. Beneficial effects of Vismodegib on tumour-stromal interactions have 
previously been  shown27, and a role for Hedgehog pathways in mesothelial-matrix interactions (as opposed to 
simple driving of cell division) is further suggested by our findings of the upregulation of PTCH2, GJB2, NHS 
and HOXA7 in SUFU deleted tumours (Table 1). These results encourage the speculation that Vismodegib may 
be of clinical use to modify mesothelioma fibrosis. Together with SUFU, two other genes were deleted at the 
same locus, ARL3 and TRIM8, the latter being involved in innate immunity.
A striking novel finding in RNA-sequencing expression data of tumours with SUFU locus deletion was the 
downregulation of T-cell and antigen-presenting cell genes (Table 1). Although unexpected, these findings were 
strongly replicated in other data (Supplementary File 1_Table 5) and are consistent with the known central func-
tion of Hedgehog signalling in T-cells at the immunological  synapse54,55.
High levels of VISTA, an alternative checkpoint inhibitor, have previously been reported in mesothelioma and 
confer a better  outcome4,39. We confirmed the strong staining for VISTA by IHC and found that VISTA abundance 
strongly correlated with other SUFU-affected immune-synapse genes. By contrast, PD-L1 staining was generally 
weak in the tumours. A small molecule inhibitor against VISTA (CA-170)56 is currently in a Phase I clinical trial 
(NCT02812875), and our findings may provide biomarkers as well as a stimulus further to investigate VISTA 
therapeutic blockade in mesothelioma.
In the same context, Vismodegib might be considered as an adjuvant to immunotherapy in the presence 
of SUFU deletion . It will be relevant to test if aberrant Hedgehog immune signalling is detectable in other 
malignancies.
It may also be of interest that the Type I Interferon genes on 9p21.3 were deleted in 52% of all mesothelioma. 
Interferons induce complex pro-inflammatory responses within tumour cells as well as in accessory immune 
 cells57,58. Homozygous deletion of IFN genes is associated with poor response to CTLA4 blockade in patients with 
malignant  melanoma59. Historically, administration of IFNA2 to patients with mesothelioma has occasionally 
induced complete  regression60,61. Supplementary, early stage trials suggest that intra-pleural infection with viral 
vectors containing IFNA262 or IFNB163 induce inflammation and encourage beneficial mesothelioma responses, 
suggesting an adjuvant role for interferons in therapy.
The association of CDKN2A deletion with higher copy number burdens might indicate a beneficial effect of 
immune checkpoint inhibitors, but the co-deletion of IFN type I could enhance tumour cell evasion of immune 
surveillance. On the other hand, the deletion of IFN genes may encourage the use of oncolytic virus as  therapies17. 
These alternatives could be explored in immunocompetent murine models of mesothelioma.
The results of our investigations should be interpreted in the light of several limitations. We were not powered 
to investigate determinants of fibrosis, an important variable feature of mesothelioma. Nevertheless, we exam-
ined tumours with tumour extent down to 20% as estimated by ASCAT analysis, compared to TCGA analysis 
of mesothelioma that was confined to tumours with only > 70% mesothelioma  cells4, providing a reference for 
one extreme of the range.
The dose of asbestos exposure is a known determinant of fibrosis, but not of  mesothelioma64. Sixty percent 
of our cases reported working with asbestos, but we did not have accurate estimates of exposure from a detailed 
occupational history or from fibre counts in unaffected lungs to include exposure as a covariate in our analysis.
Calling the presence of small or uncommon amplifications and deletions in heterogenous tumour samples 
may be problematic. The amplification segment sizes that we observed in the Infinium SNP array (with ~ 3 Kb 
spacing between SNPs) were on average seven times smaller than deletion segments (35.1 Kb vs. 265.8 Kb), and 
will have been harder to detect in the uneven coverage of WES. Nevertheless, the novel CNAs are detectable in the 
large Bueno et al.  dataset5, each showing significant associations with the abundance of their transcribed RNA.
We have shown that genomic findings correlate with protein levels in histological sections of FFPE. Notably, 
we confirmed a high level of VISTA  staining4,39 which our transcriptomic data shows to be related to Hedge-
hog aberration. We were not powered to test systematically for the determinants of histological subtypes or 
histological features which may be important in clinical decision making. Therefore, there is an unmet need for 
investigations of the relationship between histology and genomic features identified in this and other studies.
We found distinctive transcriptome changes for some common lesions (BAP1 and SUFU deletion), but not 
for lesions in the RB1 or NF2 pathways. This may be due to lack of power, or possibly to differences in gene 
expression that result from either acceleration or braking of cellular division.
We tested tool therapeutic compounds as monotherapy in patient-derived low-passage mesothelioma cells. 
We selected primary cells and cell lines for the drug screen to include the main histological subtypes of meso-
thelioma and to cover the main drivers of mesothelioma. Although the cell lines contained the most common 
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mutations, some CNAs, such as RASSF7 amplification were not found. We speculate that they may have been 
lost by weaning of pure mesothelioma cultures from other cell types. Compounds were chosen for testing to 
target the pathways shown by our genomic analysis. The known interactions of mesothelioma with stroma sug-
gest better understanding of a wider range of drug effects may come from 3D models that include fibroblasts 
and immune cells.
Conclusions
In conclusion, our analyses suggest roles for Aurora Kinase, PLK, CHEK and YAP inhibitors in the treatment 
of mesothelioma growth. IFN Type I and SUFU deletions as biomarkers may guide more effective immuno-
therapies. VISTA inhibition may directly modify immune recognition of mesothelioma, and an adjuvant role 
in immunotherapy seems possible for Hedgehog inhibitors. The involvement of Hippo and Hedgehog signals 
and the intense fibrosis seen clinically assert a central role for tumour-matrix interactions in the pathogenesis 
of mesothelioma and suggest therapeutic avenues beyond tumour cell killing.
Methods
Sample collection. Thirty unpaired tumour samples were obtained from the NIHR-BRU Advanced Lung 
Disease Biobank and Royal Brompton and the Harefield NHS Trust (RBH) Diagnostic Tissue Bank (NRES:10/
H0504/9 and 10/H0504/29-NRES Committee Southampton and South West Hampshire) from non-consecutive 
surgical biopsy samples between 2006 and 2011. Eighty-two paired (tumour and blood) and 4 unpaired tumour 
samples were obtained from MesobanK UK, Cambridge (NRES:13/EE/0169- East of England—Cambridge Cen-
tral Research Ethics Committee). Seven additional paired samples were obtained from the EQUALITY study 
(NRES:10/H0808/53- NRES Committee London-Dulwich). Samples were not collected sequentially or at set 
times, and the MesobanK specimens came from multiple centres. Tissues were collected during open or thoras-
copic surgical procedures prior to any anti-cancer treatment and were immediately snap frozen with or without 
RNAlater. Formalin-fixed paraffin embedded tissues were sectioned, stained with routine haematoxylin and 
eosin, and reviewed by two experienced pathologists to verify tumour histology and abundance. For RBH and 
EQUALITY tumours, tissues with 30% or more viable-appearing malignant cells were selected for whole exome 
sequencing (WES). MesobanK samples were selected to contain only tumours with > 50% malignant cells on his-
tology. Supplementary File 2_Table 1 contains a summary of patients’ clinico-pathologic details. All experiments 
were performed in accordance with ethical guidelines and all participants gave an informed written consent.
Genomic DNA isolation and quality control. Genomic DNA was isolated from frozen tumour tis-
sues and matched normal tissue (blood) with routine methods (Qiagen DNA and RNA extraction kits, Qiagen, 
Hilden, Germany). DNA yield and purity were assessed with the Quant-iT™ PicoGreen dsDNA Assay Kit (Life 
Technologies, Carlsbad, USA) or Qubit 3.0 fluorimeter (Thermo Scientific, Massachusetts, USA) according to 
manufacturers` protocols.
Whole exome sequencing (WES). WES was performed at the McGill Genome Centre, Canada. Genomic 
DNA from tumour and blood samples were fragmented and hybridised as per  SureSelectXT Target Enrichment 
System (Agilent SureSelect Human All Exon V4) for the Paired-End Multiplex Sequencing protocol. The cap-
tured libraries were sequenced on an Illumina HiSeq2000 according to standard protocols. Supplementary File 
2_Table 2 contains a list of somatic variants identified from whole exome sequencing.
Targeted capture sequencing of a custom gene panel. The entire coding regions of fifty-seven genes 
were included in a hybridisation capture panel (Supplementary File 1_Table 1), based on: recurrence in our 
WES tumour set; reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) database; implicated 
in  cancer65; or reported in the TCGA or Bueno et al.  studies4,5. Sequencing libraries were prepared from DNA 
extracted from tumours and normal tissue (whole blood) samples using the SureSelect QXT Target Enrichment 
System (Agilent, Santa Clara, USA) according to the manufacturer`s protocols. Sequencing was performed on a 
MiSeq or NextSeq500/550 platform (Illumina) with a mean read depth of 780.6X (all samples). Supplementary 
File 2_Table 3 contains a list of filtered somatic variants from targeted capture sequencing.
Data processing and quality control. Raw fastq files were quality checked before alignment with BWA 
mem (v 0.7.12). GATK software (v 3.8 and 4.1) was used to refine the alignment data before variant calling. For 
Targeted capture sequencing (TC-NGS), somatic and germline variant calling was performed for the paired 
samples using VarScan software (v 2.4.2). For the un-paired samples, joint variant calling was performed using 
Platypus (v 0.8.1). In case of WES, joint variant calling was performed at McGill using the GATK Haplotype-
Caller.
Detection of candidate pathogenic somatic and germline variants. Candidate somatic and 
germline variants were checked for presence in population data (gnomAD (genome Aggregation Database) 
genomes and exomes (rel.2.0.1) and the ExAC (Exome Aggregation Consortium) non-TCGA rel.0.3.1 resources) 
and those with frequency >  =  10–3 were deemed to be polymorphisms and filtered out. Additional selection was 
based on either being assigned as High or Moderate impact by  VEP66 or predicted to be splice-site altering 
 (dbscSNV67 score of > 0.6). Further prioritisation of SNV (single nucleotide variant) candidates was done based 
on predicted deleteriousness by at least two of three algorithms from SIFT, Polyphen and MutationTaster.
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Copy‑number analysis. One hundred and twenty-one DNA samples were interrogated at Eurofins against 
the Human Infinium Omni-Express-Exome v 1.3 and v 1.4 Bead Chips (Illumina) arrays containing > 950 K 
markers, using microarray technology. One hundred and eighteen samples remained (77 paired and 43 unpaired) 
after QC checks. Raw copy number data (LRR and BAF) were exported from GenomeStudio software (v 1.9.4). 
GC correction was performed to account for genomic wave artefacts affecting SNP arrays using ASCAT (v 
2.4.4). The GC corrected Log R ratios (LRR) were then processed using DNACopy (v 1.52) for segmentation and 
filtered for marker support. Recurrent germline CN segments were identified and subtracted from the tumour 
sample CN segments. Germline subtracted copy number segments were then processed with GISTIC (v 2.0.23). 
Plotting of GISTIC results was done in maftools (v 1.4.28). Copy number burden was defined as the percentage 
of the genome carrying copy number aberration. Additional information can be found in Supplementary File 
1_Supplementary Materials and methods.
Mutation signature analysis. Somatic single nucleotide variants (SNVs) from the 21 paired WES samples 
were analysed for tri-nucleotide frequency around the mutated base using  MutationalPatterns68 in R. The Sanger 
COSMIC signature panel (n = 30) was used to infer mutational processes by obtaining the percentage contribu-
tion of 30 signatures per sample. Only signatures contributing to > 25% of samples were carried forward. Paired 
germline samples were not available for whole-genome sequencing (WGS) of 19 mesothelioma primary cells 
(PMCC) (one mesothelioma primary cell WGS had failed QC), and so annotation-assisted filtering of the total 
SNVs was done. Only those SNVs that were non-polymorphic and either protein-sequence altering or predicted 
to be splice-site altering, were considered and analysed as described for the tumour tissue samples (Supplemen-
tary File 1_Fig. 6).
RNA sequencing. Total RNA was isolated from 35 tumours using the RNEasy Fibrous Midi kit (Qiagen, 
Hilden, Germany) following the manufacturer`s protocol. Concentration and quality were determined with the 
2100 Bioanalyzer and Total RNA Nano kit (Agilent Technologies, California, United States) as per manufac-
turer’s instructions. RNA sequencing was performed at McGill Genome Centre.
Replication in published data. A supplementary panel of 99 paired mesothelioma samples analysed by 
whole-exome sequencing (WES) and published by Bueno et al.5 was downloaded to investigate the presence of 
CNAs for RASSF7, RB1 and SUFU. The concurrent RNA-sequencing (RNA-seq) (98 of the WES samples) was 
also investigated for expression change in the direction of copy-number. Raw fastq reads were accessed from the 
EGA repository (EGAS00001001563). After quality-checking sequences were aligned using BWA  MEM69 and 
STAR 70 for WES and RNA-seq data respectively.  CNVkit71 was used to estimate CN calls. Mann–Whitney tests 
were used for comparisons between CNA versus CNA neutral samples.
Immunohistochemistry. Three μm whole slide FFPE tumours sections mirroring fresh frozen tissue 
used for molecular analysis underwent H& E staining according to routine histopathological protocols. Further 
sections underwent staining for BAP-1 (Santa Cruz BioTechnology,clone C4), Ki67 (Ventana, 30-9), MTAP 
(NovusBio, 2G4), PD-L1 (Ventana, SP263) and VISTA (D1L2G, Cell Signalling Technology). Mitotic activity 
was evaluated by counting the number of mitotic figures in the area of highest activity, over 10 high powered 
fields (0.24  mm2).
Whole genome sequencing of primary cell lines. Genomic DNA extracted from patient derived mes-
othelioma cell lines (n = 20, of which one failed QC) and primary normal mesothelial cells, MES-F (purchased 
from ZenBio, USA) underwent WGS (McGill) and SNP genotyping (Eurofins). Genomic details of the commer-
cial cell line were obtained from published data (COSMIC, CCLE databases, 61). Supplementary File 2_Table 4 
contains a list of variants from whole genome sequencing for the primary cells.
In vitro drug testing. Patient-derived primary cells, Meso-27T, Meso-33T and Meso-70T were obtained 
from the MRC Toxicology Unit, University of Cambridge, UK. Commercial cell lines NCI-H2052 (sarcomatoid 
mesothelioma), A549 (lung adenocarcinoma) and Met-5A (normal mesothelial, SV40 transformed) previously 
obtained from ATCC were gifted from the MRC Toxicology Unit. Original establishment of the primary cells 
was as previously  described12. Additional information can be found in Supplementary File 1_Supplementary 
Materials and Methods. All primary cells and cell lines were maintained in RPMI-1640 growth media supple-
mented with L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 μg/ml) and 10% FBS at 37 °C in 5% 
 CO2.
Eight drugs were investigated, based on our results. These were Niraparib (MK-4827, HY-10619, MedChem 
Express), Olaparib (HY-10162, MedChem Express), Palbociclib, PD0332991 (A8316, ApexBio), Alisertib 
(MLN8237, S1133, Selleckchem), Volasertib (BI6727, S2235, Selleckcehm), Vismodegib (GDC-0499, S1082, 
Selleckchem), AZD7762 (S1532, Selleckchem) and Verteporfin (SML0534, Sigma Aldrich). All drugs were diluted 
in DMSO and aliquots maintained at -20 °C. Drug aliquots were freeze-thawed no more than three times. For 
all experiments, controls consisted of DMSO-alone treated primary cells or cell lines.
Cells were seeded in 96-well plates (4 ×  103 cells/well) 24 h prior to drug treatments. Each line was treated for 
six days (except for drug PD0332991 where treatment was 3 days) with a range of concentrations from 0.0005 
to 50 μM. Cell viability was measured with MTS assay (CellTiter  96® AQueous One Solution Cell Proliferation 
Assay, Promega) on a plate reader (Tecan).
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Three independent experiments, each having three technical replicates, were conducted for each drug tested. 
Results are represented as the average normalized to the control at each time point (mean ± S.E.M.). Briefly, the 
raw optical densities obtained from each well were normalized to the average of DMSO control wells, that was 
considered 100% viability (maximal DMSO concentration used was 0.5%).  IC50 values were calculated with Graph 
Pad Prism 5 software (GraphPad Software Inc, San Diego, CA) using a dose–response curve fit model using the 
nonlinear log (inhibitor) versus response-variable slope (four parameters) equation. In addition, the  IC50 values 
were only considered if the software gave unambiguous results and the  R2 value was > 0.7.
Statistical analysis. Categorical variables were evaluated using Fisher’s exact test for two-by-two compari-
son or Pearson’s χ2 for comparison that exceeded the two-by-two condition. Differences between groups were 
evaluated by means of nonparametric Mann–Whitney or Kruskal–Wallis test.
Clinical outcomes. Overall survival (OS), defined as time from date of diagnosis to time of death, was avail-
able for 110 patients. OS was estimated using the Cox-Mantel log-rank test, Kaplan–Meier method. Censoring 
of OS was done at the date of the last follow-up if death did not occur. Survival analyses were performed using 
the long-rank Kaplan–Meier and the differences in survival curves were assessed by Mantel Cox Log rank test. A 
P ≤ 0.05 was considered statistically significant and noted as: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Tests and graphs 
were performed with Graph-Pad Prism 5, SPSS Statistics 25 or R Studio.
Ethics approval and consent to participate. All samples were collected and used under ethic and con-
sented approval to participate in the study. Thirty unpaired tumour samples were obtained from the NIHR-BRU 
Advanced Lung Disease Biobank and Royal Brompton and the Harefield NHS Trust (RBH) Diagnostic Tis-
sue Bank (NRES:10/H0504/9 and 10/H0504/29-NRES Committee Southampton and South West Hampshire) 
with eighty-two paired (tumour and blood) and 4 unpaired tumour samples obtained from MesobanK UK, 
Cambridge (NRES:13/EE/0169-East of England—Cambridge Central Research Ethics Committee). Seven Sup-
plementary paired samples were obtained from the EQUALITY study (NRES:10/H0808/53-NRES Committee 
London-Dulwich).
Data availability
The datasets generated and/or analysed during the current study have been submitted at the European Genome-
Phenome Archive (EGA) (https:// ega- archi ve. org/) under accession code: EGAS00001004845.
Received: 23 March 2021; Accepted: 2 September 2021
References
 1. Odgerel, C. O. et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup. 
Environ. Med. 74, 851–858. https:// doi. org/ 10. 1136/ oemed- 2017- 104298 (2017).
 2. Disselhorst, M. J. et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): 
Results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 7, 260–270. https:// doi. org/ 10. 1016/ S2213- 2600(18) 30420-X 
(2019).
 3. Scherpereel, A. et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-
1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 20, 239–253. https:// doi. org/ 
10. 1016/ S1470- 2045(18) 30765-4 (2019).
 4. Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548–1565. https:// 
doi. org/ 10. 1158/ 2159- 8290. CD- 18- 0804 (2018).
 5. Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions 
and splicing alterations. Nat. Genet. 48, 407–416. https:// doi. org/ 10. 1038/ ng. 3520 (2016).
 6. Rintoul, R. C., Rassl, D. M., Gittins, J. & Marciniak, S. J. MesobanK UK: An international mesothelioma bioresource. Thorax 71, 
380–382. https:// doi. org/ 10. 1136/ thora xjnl- 2015- 207496 (2016).
 7. Chernova, T. et al. Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor 
gene Cdkn2a (Ink4a/Arf). Curr. Biol. 27, 3302-3314 e3306. https:// doi. org/ 10. 1016/j. cub. 2017. 09. 007 (2017).
 8. Rehrauer, H. et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruit-
ment, RNA editing, and somatic mutations. Oncogene 37, 2645–2659. https:// doi. org/ 10. 1038/ s41388- 018- 0153-z (2018).
 9. Liu, W., Ernst, J. D. & Broaddus, V. C. Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis 
in mesothelial cells. Am. J. Respir. Cell Mol. Biol. 23, 371–378. https:// doi. org/ 10. 1165/ ajrcmb. 23.3. 4094 (2000).
 10. Upadhyay, D. & Kamp, D. W. Asbestos-induced pulmonary toxicity: Role of DNA damage and apoptosis. Exp. Biol. Med. (Maywood) 
228, 650–659 (2003).
 11. Huret, J. L. et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Res. 41, D920-924. https:// 
doi. org/ 10. 1093/ nar/ gks10 82 (2013).
 12. Chernova, T. et al. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell. Death Differ. 23, 
1152–1164. https:// doi. org/ 10. 1038/ cdd. 2015. 165 (2016).
 13. van der Bij, S. et al. Prognosis and prognostic factors of patients with mesothelioma: A population-based study. Br. J. Cancer 107, 
161–164. https:// doi. org/ 10. 1038/ bjc. 2012. 245 (2012).
 14. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration 
in human cancers. Genome Biol. 12, R41. https:// doi. org/ 10. 1186/ gb- 2011- 12-4- r41 (2011).
 15. Lopez-Rios, F. et al. Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and P16/CDKN2A 
deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66, 2970–2979. https:// 
doi. org/ 10. 1158/ 0008- 5472. CAN- 05- 3907 (2006).
 16. Nastase, A. et al. MA23.10 low number of mutations and frequent co-deletions of CDKN2A and IFN type I characterize malignant 
pleural mesothelioma. J. Thorac. Oncol. 14, S345. https:// doi. org/ 10. 1016/j. jtho. 2019. 08. 698 (2019).
 17. Delaunay, T. et al. Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic 
measles virus. J Thorac. Oncol. 15, 827–842. https:// doi. org/ 10. 1016/j. jtho. 2019. 12. 128 (2020).
13
Vol.:(0123456789)
Scientific Reports |        (2021) 11:19138  | https://doi.org/10.1038/s41598-021-98414-w
www.nature.com/scientificreports/
 18. Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. 
Cancer 17, 475–488. https:// doi. org/ 10. 1038/ nrc. 2017. 42 (2017).
 19. Felley-Bosco, E., Opitz, I. & Meerang, M. Hedgehog signaling in malignant pleural mesothelioma. Genes (Basel) 6, 500–511. https:// 
doi. org/ 10. 3390/ genes 60305 00 (2015).
 20. Lee, Y. et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 26, 6442–6447. https:// doi. org/ 10. 1038/ sj. 
onc. 12104 67 (2007).
 21. Bhaduri, U. & Merla, G. Rise of TRIM8: A molecule of duality. Mol. Ther. Nucleic Acids 22, 434–444. https:// doi. org/ 10. 1016/j. 
omtn. 2020. 08. 034 (2020).
 22. Caratozzolo, M. F., Marzano, F., Mastropasqua, F., Sbisa, E. & Tullo, A. TRIM8: Making the right decision between the oncogene 
and tumour suppressor Role. Genes (Basel) https:// doi. org/ 10. 3390/ genes 81203 54 (2017).
 23. Volodko, N., Gordon, M., Salla, M., Ghazaleh, H. A. & Baksh, S. RASSF tumor suppressor gene family: Biological functions and 
regulation. FEBS Lett. 588, 2671–2684. https:// doi. org/ 10. 1016/j. febsl et. 2014. 02. 041 (2014).
 24. Zheng, X. et al. The coiled-coil domain of oncogene RASSF 7 inhibits hippo signaling and promotes non-small cell lung cancer. 
Oncotarget 8, 78734–78748. https:// doi. org/ 10. 18632/ oncot arget. 20223 (2017).
 25. Okazaki, N., Takahashi, N., Kojima, S., Masuho, Y. & Koga, H. Protocadherin LKC, a new candidate for a tumor suppressor of 
colon and liver cancers, its association with contact inhibition of cell proliferation. Carcinogenesis 23, 1139–1148. https:// doi. org/ 
10. 1093/ carcin/ 23.7. 1139 (2002).
 26. Islam, M. A., Sooro, M. A. & Zhang, P. Autophagic regulation of p62 is critical for cancer therapy Int. J. Mol. Sci. https:// doi. org/ 
10. 3390/ ijms1 90514 05 (2018).
 27. Meerang, M. et al. Antagonizing the hedgehog pathway with vismodegib impairs malignant pleural mesothelioma growth in vivo 
by affecting stroma. Mol. Cancer Ther. 15, 1095–1105. https:// doi. org/ 10. 1158/ 1535- 7163. MCT- 15- 0583 (2016).
 28. Nakatani, K. et al. Targeting the Hippo signalling pathway for cancer treatment. J. Biochem. 161, 237–244. https:// doi. org/ 10. 1093/ 
jb/ mvw074 (2017).
 29. Woodard, G. A., Yang, Y. L., You, L. & Jablons, D. M. Drug development against the hippo pathway in mesothelioma. Transl. Lung 
Cancer Res. 6, 335–342. https:// doi. org/ 10. 21037/ tlcr. 2017. 06. 02 (2017).
 30. Azzolin, L. et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 158, 157–170. 
https:// doi. org/ 10. 1016/j. cell. 2014. 06. 013 (2014).
 31. Kato, S. et al. RET aberrations in diverse cancers: Next-generation sequencing of 4,871 patients. Clin. Cancer Res. 23, 1988–1997. 
https:// doi. org/ 10. 1158/ 1078- 0432. CCR- 16- 1679 (2017).
 32. Nass, N. et al. High neuronatin (NNAT) expression is associated with poor outcome in breast cancer. Virchows Arch 471, 23–30. 
https:// doi. org/ 10. 1007/ s00428- 017- 2154-7 (2017).
 33. Sy, S. M., Huen, M. S. & Chen, J. PALB2 is an integral component of the BRCA complex required for homologous recombination 
repair. Proc. Natl. Acad. Sci. U. S. A. 106, 7155–7160. https:// doi. org/ 10. 1073/ pnas. 08111 59106 (2009).
 34. Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: Comprehensive genome-wide analysis of mutational 
processes. Genome Medicine 10, 33. https:// doi. org/ 10. 1186/ s13073- 018- 0539-0 (2018).
 35. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421. https:// doi. org/ 10. 1038/ natur 
e12477 (2013).
 36. Doi, M. et al. Gpr176 is a Gz-linked orphan G-protein-coupled receptor that sets the pace of circadian behaviour. Nat. Commun. 
7, 10583. https:// doi. org/ 10. 1038/ ncomm s10583 (2016).
 37. Righi, L. et al. BRCA1-associated protein 1 (BAP1) Immunohistochemical expression as a diagnostic tool in malignant pleural 
mesothelioma classification: A large retrospective study. J. Thorac. Oncol. 11, 2006–2017. https:// doi. org/ 10. 1016/j. jtho. 2016. 06. 
020 (2016).
 38. Lines, J. L. et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74, 1924–1932. https:// doi. org/ 10. 1158/ 
0008- 5472. CAN- 13- 1504 (2014).
 39. Muller, S. et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint 
molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod. Pathol. 33, 303–311. https:// doi. org/ 10. 1038/ 
s41379- 019- 0364-z (2020).
 40. Mateo, J. et al. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 30, 1437–1447. https:// doi. org/ 10. 
1093/ annonc/ mdz192 (2019).
 41. Srinivasan, G. et al. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother. Pharmacol. 
80, 861–867. https:// doi. org/ 10. 1007/ s00280- 017- 3401-y (2017).
 42. Fennell, D. A. et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-
arm, phase 2a clinical trial. Lancet Respir. Med. https:// doi. org/ 10. 1016/ S2213- 2600(20) 30390-8 (2021).
 43. Witkiewicz, A. K. et al. Targeting the vulnerability of RB tumor suppressor loss in triple-negative breast cancer. Cell. Rep. 22, 
1185–1199. https:// doi. org/ 10. 1016/j. celrep. 2018. 01. 022 (2018).
 44. Romagnoli, S. et al. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression 
analysis. Am. J. Pathol. 174, 762–770. https:// doi. org/ 10. 2353/ ajpath. 2009. 080721 (2009).
 45. Oser, M. G. et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on aurora B kinase for survival. Cancer Discov. 
9, 230–247. https:// doi. org/ 10. 1158/ 2159- 8290. CD- 18- 0389 (2019).
 46. Van den Bossche, J. et al. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role 
for the tumor suppressor p53. Mol. Oncol. 13, 1196–1213. https:// doi. org/ 10. 1002/ 1878- 0261. 12477 (2019).
 47. Illei, P. B., Rusch, V. W., Zakowski, M. F. & Ladanyi, M. Homozygous deletion of CDKN2A and codeletion of the methylthioad-
enosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 9, 2108–2113 (2003).
 48. Bonelli, M. A. et al. Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in 
malignant pleural mesothelioma cells. Neoplasia 19, 637–648. https:// doi. org/ 10. 1016/j. neo. 2017. 05. 003 (2017).
 49. Kandasamy, S. et al. The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype. 
Mol. Cancer Res. 18, 343–351. https:// doi. org/ 10. 1158/ 1541- 7786. Mcr- 19- 0914 (2020).
 50. Tranchant, R. et al. Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural 
mesothelioma. Lung Cancer 126, 15–24. https:// doi. org/ 10. 1016/j. lungc an. 2018. 10. 015 (2018).
 51. Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022–1025. https:// doi. org/ 10. 
1038/ ng. 912 (2011).
 52. Ventii, K. H. et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localiza-
tion. Cancer Res. 68, 6953–6962. https:// doi. org/ 10. 1158/ 0008- 5472. CAN- 08- 0365 (2008).
 53. BLU-667 controls RET-altered thyroid cancers. Cancer Discov 9, OF5. https:// doi. org/ 10. 1158/ 2159- 8290. CD- NB2019- 084 (2019).
 54. Rowbotham, N. J. et al. Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the 
thymus and peripheral T-cell activation. Blood 109, 3757–3766. https:// doi. org/ 10. 1182/ blood- 2006- 07- 037655 (2007).
 55. de la Roche, M. et al. Hedgehog signaling controls T cell killing at the immunological synapse. Science 342, 1247–1250. https:// 
doi. org/ 10. 1126/ scien ce. 12446 89 (2013).




Scientific Reports |        (2021) 11:19138  | https://doi.org/10.1038/s41598-021-98414-w
www.nature.com/scientificreports/
 57. Borden, E. C. Interferons alpha and beta in cancer: Therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 18, 
219–234. https:// doi. org/ 10. 1038/ s41573- 018- 0011-2 (2019).
 58. Liu, H. et al. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25, 95–102. https:// 
doi. org/ 10. 1038/ s41591- 018- 0302-5 (2019).
 59. Ye, Z. et al. Prevalent homozygous deletions of type i interferon and defensin genes in human cancers associate with immunotherapy 
resistance. Clin. Cancer Res. 24, 3299–3308. https:// doi. org/ 10. 1158/ 1078- 0432. CCR- 17- 3008 (2018).
 60. Christmas, T. I., Manning, L. S., Garlepp, M. J., Musk, A. W. & Robinson, B. W. Effect of interferon-alpha 2a on malignant meso-
thelioma. J. Interferon Res. 13, 9–12 (1993).
 61. Sexl, V., Wagner, L., Wiesholzer, M., Presterl, E. & Base, W. Treatment of a patient with malignant mesothelioma with interferon-
alpha 2 based on in vitro sensitivity tests. Clin. Investig. 72, 317–320 (1994).
 62. Sterman, D. H. et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural 
delivery of adenovirus-IFNalpha combined with chemotherapy. Clin. Cancer Res. 22, 3791–3800. https:// doi. org/ 10. 1158/ 1078- 
0432. CCR- 15- 2133 (2016).
 63. Sterman, D. H. et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma 
and metastatic pleural effusions. Mol. Ther. 18, 852–860. https:// doi. org/ 10. 1038/ mt. 2009. 309 (2010).
 64. Cookson, W. O. et al. Benign and malignant pleural effusions in former Wittenoom crocidolite millers and miners. Aust. N. Z. J. 
Med. 15, 731–737 (1985).
 65. Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein 
complexes. Nat. Genet. 47, 106–114. https:// doi. org/ 10. 1038/ ng. 3168 (2015).
 66. McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122. https:// doi. org/ 10. 1186/ s13059- 016- 0974-4 (2016).
 67. Jian, X., Boerwinkle, E. & Liu, X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic 
Acids Res. 42, 13534–13544. https:// doi. org/ 10. 1093/ nar/ gku12 06 (2014).
 68. Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. Mutational patterns: Comprehensive genome-wide analysis of mutational 
processes. Genome Med. 10, 33. https:// doi. org/ 10. 1186/ s13073- 018- 0539-0 (2018).
 69. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760. 
https:// doi. org/ 10. 1093/ bioin forma tics/ btp324 (2009).
 70. Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21. https:// doi. org/ 10. 1093/ bioin forma tics/ 
bts635 (2013).
 71. Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-wide copy number detection and visualization from targeted 
DNA sequencing. PLoS Comput. Biol. 12, e1004873. https:// doi. org/ 10. 1371/ journ al. pcbi. 10048 73 (2016).
Acknowledgements
This study was financially supported by a Libor Fund grant from the UK Department of Health, by the British 
Lung Foundation and by the Asmarley Foundation. MMF, AEW, XMS and TC are funded by the UK Medical 
Research Council. SP acknowledges NHS funding to the Royal Marsden Hospital-Institute of Cancer Research 
Biomedical Research Centre. We thank Cambridge Biomedical Research Centre and Cambridge Cancer Centre.
Author contributions
W.O.C.M.C., M.F.M., M.L., S.P. and A.M.B. planned the study; A.N. processed samples and prepared libraries 
for targeted capture sequencing, post-analysed whole exome, T.C.-N.G.S., R.N.A. sequencing and I.H.C. data, 
and performed drug testing on primary cells and cell lines; A.M. performed bioinformatics analysis of whole 
exome and whole genome sequencing, targeted capture, RNA sequencing and copy number data; S.G. and S.K.L. 
processed and prepared samples for whole exome, RNA sequencing and copy number analysis; H.A. analysed 
WES data; D.M.R. and M.E. provided support in generating the TC-NGS panel and analysis of the libraries; 
A.B. performed immunohistochemistry staining, Y.Z.Z. and A.G.N. interpreted immunohistochemistry data; 
T.C., X-M.S., A.E.W. and M.M. established and characterized primary cells from tumours; M.L. oversaw whole-
exome and RNA sequencing of the samples and advised on analyses; E.L., R.C.R. and T.B. gathered samples and 
associated metadata for the study; and S.P. and A.N.T. provided clinical and epidemiological scientific guidance. 
A.N. and A.M. wrote the first draft of the manuscript with guidance by W.O.C.M.C., M.F.M. and A.M.B., before 
editing by all the other authors.
Competing interests 
SP reports honoraria from BMS, Roche, Takea, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, 
Guardant Health, AbbVie, Boehringer Ingleheim, and Tesaro. All other authors have no competing interests 
to declare.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 98414-w.
Correspondence and requests for materials should be addressed to M.F.M. or W.O.C.M.C.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific Reports |        (2021) 11:19138  | https://doi.org/10.1038/s41598-021-98414-w
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
